These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23654152)

  • 1. [Dapagliflozin. Lowering blood glucose levels by increasing glucosuria].
    Hinneburg I
    Med Monatsschr Pharm; 2013 Apr; 36(4):128-32. PubMed ID: 23654152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin: glucuretic action and beyond.
    Balakumar P; Sundram K; Dhanaraj SA
    Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dapagliflozin, a novel oral antidiabetic with an uncertain future].
    Escudero Vilaplana B; Almodóvar Carretón MJ; Herrero Hernández S
    Farm Hosp; 2014 Nov; 38(6):468-74. PubMed ID: 25542657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.
    Andrianesis V; Doupis J
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):519-39. PubMed ID: 23978089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin for the treatment of type 2 diabetes.
    Anderson SL; Marrs JC
    Ann Pharmacother; 2012 Apr; 46(4):590-8. PubMed ID: 22433611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
    Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
    Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
    Tang W; Reele S; Hamer-Maansson JE; Parikh S; de Bruin TW
    Diabetes Obes Metab; 2015 Apr; 17(4):423-5. PubMed ID: 25511685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin for the treatment of type 2 diabetes.
    Brooks AM; Thacker SM
    Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes drugs ride a bumpy road.
    Ledford H
    Nature; 2013 Dec; 504(7479):198. PubMed ID: 24336264
    [No Abstract]   [Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
    Rizos EC; Elisaf MS
    Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(4):263. PubMed ID: 24481146
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecule of the month. Dapagliflozin.
    Drug News Perspect; 2007 Dec; 20(10):645. PubMed ID: 18301798
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
    Tan X; Hu J
    Expert Opin Pharmacother; 2016; 17(1):117-26. PubMed ID: 26567559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
    Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
    Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
    Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
    Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.